

Endometrial Cancer EBRT Decision Tree : Updated March 2013

<b>Endometrial Cancer</b> <b>ECRIC 2772</b>	<b>Stage I</b> <b>ECRIC 77%</b>	<b>IA T1a</b> Tumour limited to endometrium or invades less than ½ of myometrium [old Figo IA and IB]	Surgery <b>ECRIC 95%</b>	No XBRT If Low or intermediate <sup>1</sup> risk <b>ECRIC 75%</b>
		<b>IB T1b</b> Tumour invades ≥ ½ of myometrium [old Figo IC]	Medically inoperable <b>5% ECRIC</b>	Vaginal Brachytherapy[VB] if high risk-consider XBRT <sup>1</sup> i.e. for Grade 3 [For IB Gd I +2 VB, XBRT <sup>1</sup> 46 Gy/23# <sup>*</sup> , or 45 Gy/25# <b>ECRIC 25%</b> Gd 3 VB and Rt] Radiotherapy 45 Gy/25# [VB] if fit <b>ECRIC 14%</b> No radiotherapy for unfit <b>ECRIC 86%</b>
	<b>Stage II</b> <b>ECRIC 9%</b>	<b>II T2</b> Tumour invades stromal connective tissue of the cervix but does not invade beyond the cervix [old Figo IIa and IIb]	Surgery <b>ECRIC 93%</b>	No Radiotherapy <b>ECRIC 30%</b>
			Medically inoperable No surgery <b>ECRIC 7%</b>	XBRT <sup>2,3,4</sup> 40-46* Gy/23-25#, 45 Gy/25#, VB <b>ECRIC 70%</b> XBRT <sup>2,3,4</sup> 40-46 *Gy/23-25#, 45 Gy/25#, VB <b>ECRIC 33%</b> <b>ECRIC no RT 67%</b>
	<b>Stage III</b> <b>ECRIC 9%</b>	<b>IIIA T3a</b> Tumour involves serosa and or adnexa [direct extension or metastasis] <b>IIIB T3b</b> Vaginal involvement [direct extension or metastasis]or parametrial involvement <b>IIIC</b> Metastases to pelvic +/- para-aortic lymph nodes	Surgery <b>78% ECRIC</b>	No Radiotherapy. <b>ECRIC 59%</b> Patient preference, poor PS, contraindication. XBRT 40-46* Gy/23-25#, 45 Gy/25#, <b>ECRIC 41%</b> VB
			Medically inoperable <b>ECRIC 22%</b>	XBRT 40-46* Gy/23-25#, 45 Gy/25#, VB <b>ECRIC 30%</b> <b>ECRIC no RT 70%</b>
			Consider preoperative CT, maximal debulking, young pt, good PS. May give RT	XBRT 45 Gy/25 # to pelvis and boost to 60 Gy to residual tumour. <b>ECRIC surgery then adj. RT 18%</b> <b>ECRIC surgery then no adj. RT 82 %</b>
	<b>Stage IV</b> <b>ECRIC 5%</b>	<b>IVA T4</b> Tumour invades mucosa of bladder and/or bowel <b>ECRIC 35%</b>	If good PS and symptoms	Palliative RT-Bleeding 6-8 Gy/1#, pain 20 Gy/5#, 30 Gy/10# , Bone metastases 8 Gy/1#, 20 Gy/5#, spinal cord compression 20 Gy/5# <b>ECRIC RT 20%</b> <b>ECRIC No RT 80%</b>
		<b>IVB</b> Distant metastasis [includes metastasis to inguinal Ln's intraperitoneal disease, lung, liver, or bone. Excludes metastasis to para-aortic Ln's, vagina, pelvic serosa and adnexa <b>ECRIC 65%</b>		

## References: Endometrial Cancer

1. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, De Winter KA, Lutgens LC, van den Bergh AC, van de Steen-Banasik E, Beerman H, van Lent M. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. *Lancet*. 2000 Apr 22;355(9213):1404-11
2. Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, Pearlman A, Maiman MA, Bell JG; Gynecologic Oncology Group A. Phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol*. 2004 Mar;92(3):744-51
3. Nout RA, Smit VT, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Mens JW, Slot A, Kroese MC, van Bunningen BN, Ansink AC, van Putten WL, Creutzberg CL; PORTEC Study Group. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. *Lancet*. 2010 Mar 6;375(9717):816-23
4. EC/EN.5 Study Group, Blake P, Swart AM, Orton J, Kitchener H, Whelan T, Lukka H, Eisenhauer E, Bacon M, Tu D, Parmar MK, Amos C, Murray C, Qian W. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. *Lancet*. 2009 Jan 10;373(9658):137-46. Epub 2008 Dec 16.
5. Lukka H, Chambers A, Fyles A, Thephamongkhon K, Fung-Kee-Fung M, Elit L, Kwon J. Adjuvant radiotherapy in women with stage I endometrial cancer: a systematic review. *Gynecol Oncol*. 2006 Aug;102(2):361-8. Epub 2006 May 2.
6. Rankins NC, Secord AA, Jewell E, Havrilesky LJ, Soper JT, Myers E. Cost-effectiveness of adjuvant radiotherapy in intermediate risk endometrial cancer. *Gynecol Oncol*. 2007 Aug;106(2):388-93. Epub 2007 May 16.
7. Baekelandt MM, Castiglione M; **ESMO Guidelines Working Group**. Endometrial carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. *Ann Oncol*. 2009 May;20 Suppl 4:29-31.
8. British Columbia Cancer Agency. Radiation - Endometrioid Type. <http://www.bccancer.bc.ca/HPI/CancerManagementGuidelines/Gynecology/Endometrioid/Mngmt.htm>
9. The Royal College of Radiologists. Radiotherapy dose-fractionation. The Royal College of Radiologists, London, 2006. <http://www.rcr.ac.uk/publications>
10. NCCN Guidelines™ <http://www.nccn.org/index.asp>